![[höher]](/style/images/multi_up.png)
Eine Ebene höherGruppiert nach: Dokumententyp |
Veröffentlichungsdatum
Anzahl der Publikationen: 5
2021
Casulo, Carla; Dixon, Jesse G.; Ou, Fang-Shu; Hoster, Eva; Peterson, Bruce A.; Hochster, Howard S.; Brice, Pauline; Ladetto, Marco; Hiddemann, Wolfgang; Marcus, Robert; Kimby, Eva; Herold, Michael; Nielsen, Tina; Morschhauser, Franck; Rummel, Mathias; Hagenbeek, Anton; Vitolo, Umberto; Salles, Gilles A.; Shi, Qian und Flowers, Christopher R.
(2021):
Outcomes of older patients with follicular lymphoma using individual data from 5922 patients in 18 randomized controlled trials.
In: Blood Advances, Bd. 5, Nr. 6: S. 1737-1745
2019
Rosenwald, Andreas; Bens, Susanne; Advani, Ranjana; Barrans, Sharon; Copie-Bergman, Christiane; Elsensohn, Mad-Helenie; Natkunam, Yaso; Calaminici, Maria; Sander, Birgitta; Baia, Maryse; Smith, Alexandra; Painter, Daniel; Pham, Luu; Zhao, Shuchun; Ziepert, Marita; Jordanova, Ekaterina S.; Molina, Thierry J.; Kersten, Marie José; Kimby, Eva; Klapper, Wolfram; Raemaekers, John; Schmitz, Norbert; Jardin, Fabrice; Stevens, Wendy B. C.; Hoster, Eva; Hagenbeek, Anton; Gribben, John G.; Siebert, Reiner; Gascoyne, Randy D.; Scott, David W.; Gaulard, Philippe; Salles, Gilles; Burton, Catherine; Jong, Daphne de; Sehn, Laurie H. und Maucort-Boulch, Delphine
(2019):
Prognostic Significance of MYC Rearrangement and Translocation Partner in Diffuse Large B-Cell Lymphoma: A Study by the Lunenburg Lymphoma Biomarker Consortium.
In: Journal of Clinical Oncology, Bd. 37, Nr. 35: S. 3359-3368
Morschhauser, Franck; Flinn, Ian W.; Advani, Ranjana; Sehn, Laurie H.; Diefenbach, Catherine; Kolibaba, Kathryn; Press, Oliver W.; Salles, Gilles; Tilly, Herve; Chen, Andy I.; Assouline, Sarit; Cheson, Bruce D.; Dreyling, Martin; Hagenbeek, Anton; Zinzani, Pier Luigi; Jones, Surai; Cheng, Ji; Lu, Dan; Penuel, Elicia; Hirata, Jamie; Wenger, Michael; Chu, Yu-Waye und Sharman, Jeff
(2019):
Polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed or refractory non-Hodgkin lymphoma: final results from a phase 2 randomised study (ROMULUS).
In: Lancet Haematology, Bd. 6, Nr. 5, E254-E265
2017
Shi, Qian; Flowers, Christopher R.; Hiddemann, Wolfgang; Marcus, Robert; Herold, Michael; Hagenbeek, Anton; Kimby, Eva; Hochster, Howard; Vitolo, Umberto; Peterson, Bruce A.; Gyan, Emmanuel; Ghielmini, Michele; Nielsen, Tina; Bedout, Sabine de; Fu, Tommy; Valente, Nancy; Fowler, Nathan H.; Hoster, Eva; Ladetto, Marco; Morschhauser, Franck; Zucca, Emanuele; Salles, Gilles und Sargent, Daniel J.
(10. Februar 2017):
Thirty-Month Complete Response as a Surrogate End Point in First-Line Follicular Lymphoma Therapy: An Individual Patient-Level Analysis of Multiple Randomized Trials.
In: Journal of clinical oncology, Bd. 35, Nr. 5: S. 552-560
Stevens, Wendy B. C.; Mendeville, Matias; Redd, Robert; Clear, Andrew J.; Bladergroen, Reno; Calaminici, Maria; Rosenwald, Andreas; Hoster, Eva; Hiddemann, Wolfgang; Gaulard, Philippe; Xerri, Luc; Salles, Gilles; Klapper, Wolfram; Pfreundschuh, Michael; Jack, Andrew; Gascoyne, Randy D.; Natkunam, Yasodha; Advani, Ranjana; Kimby, Eva; Sander, Birgitta; Sehn, Laurie H.; Hagenbeek, Anton; Raemaekers, John; Gribben, John; Kersten, Marie José; Ylstra, Bauke; Weller, Edie und Jong, Daphne de
(2017):
Prognostic relevance of CD163 and CD8 combined with EZH2 and gain of chromosome 18 in follicular lymphoma: a study by the Lunenburg Lymphoma Biomarker Consortium.
In: Haematologica, Bd. 102, Nr. 8: S. 1413-1423